What to Expect: Merck, Gilead Sciences, and Bristol-Myers Squibb Earnings on Deck
- April 20th, 2025
- 1065 views
Notable companies expected to release their financial results on Thursday, April 24, include:
Merck & Co., Inc. (NYSE: MRK), known for its innovative portfolio of prescription medicines and vaccines, will report its first-quarter 2025 earnings before the U.S. markets open. Analysts expect earnings per share (EPS) of $2.14 on revenue of $15.33 billion. $MRK rose 2.01% (+$1.54) to close at $78.00 on Thursday.
Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company focused on antiviral treatments and oncology, will announce its first-quarter 2025 financial results after market close. Wall Street anticipates EPS of $1.75 and revenue of $6.79 billion. $GILD dipped 0.33% (-$0.35) to finish at $104.53 on Thursday.
Bristol-Myers Squibb Company (NYSE: BMY), a major name in the pharmaceutical space, is set to release its Q1 2025 earnings before the opening bell. The consensus forecast stands at $1.52 EPS on $10.75 billion in revenue. $BMY edged lower by 0.26% (-$0.13), closing Thursday at $49.23.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login